Ultrasound Applicability in the Assessment of Patients With Fibrosing Interstitial Lung Disease (NCT06844331) | Clinical Trial Compass
By InvitationNot Applicable
Ultrasound Applicability in the Assessment of Patients With Fibrosing Interstitial Lung Disease
Denmark117 participantsStarted 2024-10-21
Plain-language summary
In this study the investigators want to examine the different ultrasound techniques to assess the patients with lung fibrosis.
The investigators want to followup these patients in 1 year to see the changes in lungs, pleura, diaphragm and measurments of overarm and thigh muscles to see that the investigators can identify the patients with lung fibrosis with this methods and monitor the progression.
Now a days the CT scan in the lungs needs to monitor these participants, but the investigators want to see the ultrasound can use insted for CT scanning to minitor these pateints.
These patient group has very bad prognosis, so it is necessary to identify these patients as early as possible to treatments.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients must be over 18 years.
* Diagnosis of IPF obtained on a multidisciplinary team conference .
* Diagnosis of PPF according to 2022 ATS/ERS/JRS/ALAT Clinical Practice Guideline.
* Ability for subject to comply with the requirements of the study.
* Informed consent.
Exclusion Criteria:
* Patients not willing to or able to give informed consent.
* Acute exacerbation in F-ILD \< 4 weeks.
* Pregnant and breastfeeding mothers
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Changes in Thoracic ultrasound/ ultrasound (TUS/US) measurments over 12 months in patients with F-ILD.
Timeframe: 12 months. The investigator group will examine patients in baseline (Day 0), after 6 months (day 180) and after 12 months (day 365).